Abstract:Activation of Mechanistic target of rapamycin (mTOR) signaling plays a crucial role in tumorigenesis of numerous malignancies including glioblastoma (GB). The Canonical PI3K/Akt/mTOR signaling cascade is commonly upregulated due to loss of the tumor suppressorm PTEN, a phosphatase that acts antagonistically to the kinase (PI3K) in conversion of PIP2 to PIP3. mTOR forms two multiprotein complexes, mTORC1 and mTORC2 which are composed of discrete protein binding partners to regulate cell growth, motility, and metabolism. These complexes are sensitive to distinct stimuli, as mTORC1 is sensitive to nutrients while mTORC2 is regulated via PI3K and growth factor signaling. The main function of mTORC1 is to regulate protein synthesis and cell growth through downstream molecules: 4E-BP1 (also called EIF4E-BP1) and S6K. On the other hand, mTORC2 is responsive to growth factor signaling by phosphorylating the C-terminal hydrophobic motif of some AGC kinases like Akt and SGK and it also plays a crucial role in maintenance of normal and cancer cells through its association with ribosomes, and is involved in cellular metabolic regulation. mTORC1 and mTORC2 regulate each other, as shown by the fact that Akt regulates PRAS40 phosphorylation, which disinhibits mTORC1 activity, while S6K regulates Sin1 to modulate mTORC2 activity. Allosteric inhibitors of mTOR, rapamycin and rapalogs, remained ineffective in clinical trials of Glioblastoma (GB) patients, in part due to their incomplete inhibition of mTORC1 as well as unexpected activation of mTOR via the loss of negative feedback loops. In recent years, novel ATP binding inhibitors of mTORC1 and mTORC2 suppress mTORC1 activity completely by total dephosphorylation of its downstream substrate pS6KSer235/236, while effectively suppressing mTORC2 activity, as demonstrated by complete dephosphorylation of pAKTSer473. Furthermore by these novel combined mTORC1/mTORC2 inhibitors reduced the proliferation and self-renewal of GB cancer stem cells. However, a search of more effective way to target mTOR has generated a third generation inhibitor of mTOR, "Rapalink", that bivalently combines rapamycin with an ATP-binding inhibitor, which effectively abolishes the mTORC1 activity. All in all, the effectiveness of inhibitors of mTOR complexes can be judged by their ability to suppress both mTORC1/mTORC2 and their ability to impede both cell proliferation and migration along with aberrant metabolic pathways.

GPCR Signaling Inhibits Mtorc1 Via PKA Phosphorylation of Raptor

AKAP13 Couples GPCR Signaling to Mtorc1 Inhibition

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

Substrate-specific regulation of mTORC1 activity by G protein-coupled receptors

Regulation Of Mtorc1 By The Rab And Arf Gtpases

AMPK-dependent Phosphorylation of the GATOR2 Component WDR24 Suppresses Glucose-Mediated Mtorc1 Activation.

Regulation of mTORC1 by Upstream Stimuli

Regulatory Function of Phosphorylation and Ubiquitination on The TORC1 Signaling Pathway

O-GlcNAcylation of Raptor transduces glucose signals to mTORC1

Abstract PR02: Structural and Functional Analyses of GATOR1, a Negative Regulator of the Mtorc1 Pathway

mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1

Post-translational Regulation of the Mtorc1 Pathway: A Switch That Regulates Metabolism-Related Gene Expression

CDK5-PRMT1-WDR24 signaling cascade promotes mTORC1 signaling and tumor growth

Arg-78 of Nprl2 Catalyzes GATOR1-stimulated GTP Hydrolysis by the Rag GTPases

Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship

Mtorc1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress

Control of Leucine-Dependent Mtorc1 Pathway Through Chemical Intervention of Leucyl-Trna Synthetase and RagD Interaction

Inhibition of Mtorc1 Signaling Sensitizes Hepatocellular Carcinoma Cells to Glycolytic Stress

Mtorc1 Alters the Expression of Glycolytic Genes by Regulating Kpna2 Abundances